Important Information

This website is managed by Ultima Markets’ international entities, and it’s important to emphasise that they are not subject to regulation by the FCA in the UK. Therefore, you must understand that you will not have the FCA’s protection when investing through this website – for example:

  • You will not be guaranteed Negative Balance Protection
  • You will not be protected by FCA’s leverage restrictions
  • You will not have the right to settle disputes via the Financial Ombudsman Service (FOS)
  • You will not be protected by Financial Services Compensation Scheme (FSCS)
  • Any monies deposited will not be afforded the protection required under the FCA Client Assets Sourcebook. The level of protection for your funds will be determined by the regulations of the relevant local regulator.

Note: UK clients are kindly invited to visit https://www.ultima-markets.co.uk/. Ultima Markets UK expects to begin onboarding UK clients in accordance with FCA regulatory requirements in 2026.

If you would like to proceed and visit this website, you acknowledge and confirm the following:

  • 1.The website is owned by Ultima Markets’ international entities and not by Ultima Markets UK Ltd, which is regulated by the FCA.
  • 2.Ultima Markets Limited, or any of the Ultima Markets international entities, are neither based in the UK nor licensed by the FCA.
  • 3.You are accessing the website at your own initiative and have not been solicited by Ultima Markets Limited in any way.
  • 4.Investing through this website does not grant you the protections provided by the FCA.
  • 5.Should you choose to invest through this website or with any of the international Ultima Markets entities, you will be subject to the rules and regulations of the relevant international regulatory authorities, not the FCA.

Ultima Markets wants to make it clear that we are duly licensed and authorised to offer the services and financial derivative products listed on our website. Individuals accessing this website and registering a trading account do so entirely of their own volition and without prior solicitation.

By confirming your decision to proceed with entering the website, you hereby affirm that this decision was solely initiated by you, and no solicitation has been made by any Ultima Markets entity.

I confirm my intention to proceed and enter this website

Important Notice

Ultima Markets does not have an establishment in Singapore and does not operate from Singapore.

Ultima Markets does not provide products or services to citizens or residents of Singapore, and account applications from Singapore citizens or residents will not be accepted.

If you are a citizen or resident of Singapore, please do not open an account or use Ultima Markets’ products or services.

By selecting “Acknowledge and Continue Browsing”, you confirm that you are accessing this website on your own initiative and that your access is not the result of any direct marketing, targeted advertising, solicitation, or promotional activity by Ultima Markets.

Nothing on this website constitutes an offer, solicitation, or promotion of products or services in any jurisdiction where such activity is prohibited. You are responsible for ensuring that your access to and use of this website complies with applicable local laws and regulations.

Acknowledge and Enter the Website

Moderna Stock Jumps Over Astounding Profits 

um editor

UM Editor

February 23, 2024 at 11:17 am

Shares of Moderna (MRNA.US) experienced a significant increase on Thursday as it reported a surprising profit and surpassed Wall Street’s quarterly forecasts. The Covid vaccine producer announced earnings of $0.55 per share on $2.8 billion in revenue for the fourth quarter, shattering FactSet analysts’ predictions of a $0.99 per share loss on $2.5 billion in sales. 

According to Chief Financial Officer Jamey Mock, this unexpected earnings result is partially due to a $600 million deferral in revenue. In a promising turn of events, Moderna continues to deliver on its pledge to trim its expenses. The expense for goods sold over the past year was noted to be $4.7 billion, undercutting the estimated figure of $5 billion. Nonetheless, the firm’s sales during the fourth quarter underwent a 45% reduction on a year-on-year basis, a dip largely attributed to the decreased sales of the company’s Covid-19 vaccine, as stated in Moderna’s press release. Correspondingly, the earnings also faced an 85% downfall. 

For the entire 2023, Moderna disclosed revenues of $6.8 billion, which is a 64% decrease when compared with the previous year, and a per-share loss of $12.33, a stark contrast to the $20.12 earnings per share registered in 2022. 

Moderna is currently seeking new opportunities by focusing on its mRNA technology for developing other pharmaceuticals, which include a respiratory syncytial virus (RSV) vaccine that is ready to challenge vaccines from two leading competitors — Pfizer (PFE.US) and GSK (GSK.US). 

Moderna stock jumped 13.5% to 99.44, following earnings releases. As for prospects, Moderna reaffirmed its forecast of $4 billion in sales for 2024, accompanied by research and development costs amounting to $4.5 billion. 

(Moderna Stock Performance One-year Chart) 

Disclaimer  

Comments, news, research, analysis, price, and all information contained in the article only serve as general information for readers and do not suggest any advice. Ultima Markets has taken reasonable measures to provide up-to-date information, but cannot guarantee accuracy, and may modify without notice. Ultima Markets will not be responsible for any loss incurred due to the application of the information provided. 

Why Trade Metals & Commodities with Ultima Markets?

Ultima Markets provides the foremost competitive cost and exchange environment for prevalent commodities worldwide.

Start Trading

  • Monitoring the market on the go

  • Markets are susceptible to changes in supply and demand

  • Attractive to investors only interested in price speculation

  • Deep and diverse liquidity with no hidden fees

  • No dealing desk and no requotes

  • Fast execution via Equinix NY4 server

Hi, how can we help you?
打开 linee 的二维码